These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 10415147

  • 21. ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
    Shiosaki K, Jenner P, Asin KE, Britton DR, Lin CW, Michaelides M, Smith L, Bianchi B, Didomenico S, Hodges L, Hong Y, Mahan L, Mikusa J, Miller T, Nikkel A, Stashko M, Witte D, Williams M.
    J Pharmacol Exp Ther; 1996 Jan; 276(1):150-60. PubMed ID: 8558425
    [Abstract] [Full Text] [Related]

  • 22. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
    Löschmann PA, Wüllner U, Heneka MT, Schulz JB, Kunow M, Wachtel H, Klockgether T.
    Synapse; 1997 Aug; 26(4):381-91. PubMed ID: 9215597
    [Abstract] [Full Text] [Related]

  • 23. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
    Pearce RK, Jackson M, Smith L, Jenner P, Marsden CD.
    Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992
    [Abstract] [Full Text] [Related]

  • 24. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
    Johnston TH, Fox SH, McIldowie MJ, Piggott MJ, Brotchie JM.
    J Pharmacol Exp Ther; 2010 Jun; 333(3):865-73. PubMed ID: 20231306
    [Abstract] [Full Text] [Related]

  • 25. The effects of D1 and D2 dopamine receptor agonist and antagonist on parkinsonism in chronic MPTP-treated monkeys.
    Nomoto M, Fukuda T.
    Adv Neurol; 1993 Jun; 60():119-22. PubMed ID: 8093574
    [No Abstract] [Full Text] [Related]

  • 26. Effects of talipexole on contraversive rotation and functional impairment in MPTP-induced chronic hemiparkinsonian monkeys.
    Domino EF, Ni L, Zhang H, Kohno Y, Sasa M.
    Jpn J Pharmacol; 1998 Jul; 77(3):227-33. PubMed ID: 9717770
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. [Dopa-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated hemiparkinsonian monkeys].
    Chen S.
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1992 Feb; 25(1):50-2, 64. PubMed ID: 1591961
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Talipexole or pramipexole combinations with chloro-APB (SKF 82958) in MPTP-induced hemiparkinsonian monkeys.
    Domino EF, Ni L, Zhang H, Kohno Y, Sasa M.
    Eur J Pharmacol; 1997 May 01; 325(2-3):137-44. PubMed ID: 9163560
    [Abstract] [Full Text] [Related]

  • 31. The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets.
    Uchida S, Soshiroda K, Okita E, Kawai-Uchida M, Mori A, Jenner P, Kanda T.
    Eur J Pharmacol; 2015 Jan 15; 747():160-5. PubMed ID: 25499739
    [Abstract] [Full Text] [Related]

  • 32. Blockade of globus pallidus adenosine A(2A) receptors displays antiparkinsonian activity in 6-hydroxydopamine-lesioned rats treated with D(1) or D(2) dopamine receptor agonists.
    Simola N, Fenu S, Baraldi PG, Tabrizi MA, Morelli M.
    Synapse; 2008 May 15; 62(5):345-51. PubMed ID: 18297692
    [Abstract] [Full Text] [Related]

  • 33. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.
    Brain; 2008 Dec 15; 131(Pt 12):3380-94. PubMed ID: 18952677
    [Abstract] [Full Text] [Related]

  • 34. L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
    Huot P, Johnston TH, Koprich JB, Aman A, Fox SH, Brotchie JM.
    J Pharmacol Exp Ther; 2012 Aug 15; 342(2):576-85. PubMed ID: 22619253
    [Abstract] [Full Text] [Related]

  • 35. Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys.
    Bédard PJ, Gomez-Mancilla B, Blanchette P, Gagnon C, Falardeau P, DiPaolo T.
    Adv Neurol; 1993 Aug 15; 60():113-8. PubMed ID: 8093573
    [No Abstract] [Full Text] [Related]

  • 36. The effects of a selective dopamine D2 receptor agonist on behavioral and pathological outcome in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated squirrel monkeys.
    Stephenson DT, Meglasson MD, Connell MA, Childs MA, Hajos-Korcsok E, Emborg ME.
    J Pharmacol Exp Ther; 2005 Sep 15; 314(3):1257-66. PubMed ID: 15980058
    [Abstract] [Full Text] [Related]

  • 37. Effects of ropinirole on motor behavior in MPTP-treated common marmosets.
    Fukuzaki K, Kamenosono T, Kitazumi K, Nagata R.
    Pharmacol Biochem Behav; 2000 Sep 15; 67(1):121-9. PubMed ID: 11113491
    [Abstract] [Full Text] [Related]

  • 38. Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure.
    Smith LA, Jackson MJ, Hansard MJ, Maratos E, Jenner P.
    Mov Disord; 2003 May 15; 18(5):487-95. PubMed ID: 12722161
    [Abstract] [Full Text] [Related]

  • 39. Estradiol and dehydroepiandrosterone potentiate levodopa-induced locomotor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Bélanger N, Grégoire L, Bédard P, Di Paolo T.
    Endocrine; 2003 Jun 15; 21(1):97-101. PubMed ID: 12777709
    [Abstract] [Full Text] [Related]

  • 40. The effects of central aromatic amino acid DOPA decarboxylase inhibition on the motor actions of L-DOPA and dopamine agonists in MPTP-treated primates.
    Treseder SA, Jackson M, Jenner P.
    Br J Pharmacol; 2000 Apr 15; 129(7):1355-64. PubMed ID: 10742291
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.